Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kiyoshi, Masato ^a   Caaveiro, Jose M M ^a   Kawai, Takeaki ^a   Tashiro, Shinya ^a   Ide, Teruhiko ^b,c   Asaoka, Yoshiharu ^b   Hatayama, Kouta ^c   Tsumoto, Kouhei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOSOH CORPORATION   (Japan)

^c SAGAMI CHEMICAL RESEARCH CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G1; FCGR1A PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ADAPTATION; CRYSTAL STRUCTURE; HYDROPHOBICITY; IMMUNE RESPONSE; MOLECULAR ANALYSIS; PROTEIN; REACTION KINETICS; THERMODYNAMICS;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISSOCIATION RATE CONSTANT; DISULFIDE BOND; HINGE REGION; HUMAN; MOLECULAR INTERACTION; MOLECULE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; TEMPERATURE DEPENDENCE; AMINO ACID SEQUENCE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; HUMANS; IMMUNOGLOBULIN G; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, IGG; SURFACE PLASMON RESONANCE;

EID: 84928776106     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7866     Document Type: Article

References (61)

1. Raghavan, M. & Bjorkman, P. J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12, 181-220 (1996).
2. Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34-47 (2008).
3. Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H. & Lambrecht, B. N. The function of Fcg receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14, 94-108 (2014).
4. Woof, J. M. & Burton, D. R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4, 89-99 (2004).
5. Fridman, W. H. et al. Structural bases of Fc gamma receptor functions. Immunol. Rev. 125, 49-76 (1992).
6. Salmon, J. E. & Pricop, L. Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease. Arthritis Rheum. 44, 739-750 (2001).
7. Bruhns, P. et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2009).
8. Nimmerjahn, F. & Ravetch, J. V. Fcgamma receptors: old friends and new family members. Immunity 24, 19-28 (2006).
9. Hogarth, P. M. & Pietersz, G. A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11, 311-331 (2012).
10. Li, X. & Kimberly, R. P. Targeting the Fc receptor in autoimmune disease. Expert Opin. Ther. Targets 18, 335-350 (2014).
11. Takai, T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580-592 (2002).
12. Takai, T. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25, 1-18 (2005).
13. Li, Y. et al. Increased expression of FcgammaRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res. Ther. 11, R6 (2009).
14. Harrison, P. T., Davis, W., Norman, J. C., Hockaday, A. R. & Allen, J. M. Binding of monomeric immunoglobulin G triggers Fc gamma RI-mediated endocytosis. J. Biol. Chem. 269, 24396-24402 (1994).
15. Guyre, P. M., Graziano, R. F., Vance, B. A., Morganelli, P. M. & Fanger, M. W. Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J. Immunol. 143, 1650-1655 (1989).
16. Uciechowski, P. et al. IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. Eur. J. Immunol. 28, 2928-2935 (1998).
17. van der Poel, C. E., Spaapen, R. M., van de Winkel, J. G. & Leusen, J. H. Functional characteristics of the high affinity IgG receptor, FcgRI. J. Immunol. 186, 2699-2704 (2011).
18. Wallace, P. K. et al. Humanized mAb H22 binds the human high affinity Fc receptor for IgG (FcgammaRI), blocks phagocytosis, and modulates receptor expression. J. Leukoc. Biol. 62, 469-479 (1997).
19. Beekman, J. M., van der Linden, J. A., van de Winkel, J. G. & Leusen, J. H. FcgammaRI (CD64) resides constitutively in lipid rafts. Immunol. Lett. 116, 149-155 (2008).
20. Fanger, N. A. et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J. Immunol. 158, 3090-3098 (1997).
21. Duchemin, A. M., Ernst, L. K. & Anderson, C. L. Clustering of the high affinity Fc receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated gamma-chain. J. Biol. Chem. 269, 12111-12117 (1994).
22. Li, Y. et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res. Ther. 12, R90 (2010).
23. Indik, Z. K. et al. The high affinity Fc gamma receptor (CD64) induces phagocytosis in the absence of its cytoplasmic domain: the gamma subunit of Fc gamma RIIIA imparts phagocytic function to Fc gamma RI. Exp. Hematol. 22, 599-606 (1994).
24. Davis, W., Harrison, P. T., Hutchinson, M. J. & Allen, J. M. Two distinct regions of FC gamma RI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J. 14, 432-441 (1995).
25. Duncan, A. R., Woof, J. M., Partridge, L. J., Burton, D. R. & Winter, G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332, 563-564 (1988).
26. Sondermann, P., Kaiser, J. & Jacob, U. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309, 737-749 (2001).
27. Radaev, S. & Sun, P. Recognition of immunoglobulins by Fc gamma receptors. Mol. Immunol. 38, 1073-1083 (2002).
28. Lu, J., Ellsworth, J. L., Hamacher, N., Oak, S. W. & Sun, P. D. Crystal structure of Fcg receptor I and its implication in high affinity g-immunoglobulin binding. J. Biol. Chem. 286, 40608-40613 (2011).
29. Ramsland, P. A. et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 187, 3208-3217 (2011).
30. Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl Acad. Sci. USA 108, 12669-12674 (2011).
31. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267-273 (2000).
32. Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C. & Sun, P. D. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 276, 16469-16477 (2001).
33. Mimoto, F. et al. Engineered antibody Fc variant with selectively enhanced FcRIIb binding over both FcRIIa(R131) and FcRIIa(H131). Prot. Eng 26, 589-598 (2013).
34. Ioan-Facsinay, A. et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16, 391-402 (2002).
35. Liu, Z. et al. Asymmetrical Fc engineering greatly enhances antibodydependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 289, 3571-3590 (2014).
36. Masuda, K. et al. Enhanced binding affinity for FcgammaRIIIa of fucosenegative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol. Immunol. 44, 3122-3131 (2007).
37. Mimoto, F. et al. Novel asymmetrically engineered antibody Fc variant with superior FcgR binding affinity and specificity compared with afucosylated Fc variant. MAbs 5, 229-236 (2013).
38. Mimoto, F. et al. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcgRs. Mol. Immunol. 58, 132-138 (2014).
39. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein-protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
40. Lu, J. et al. Structure of FcgammaRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding. Proc. Natl Acad. Sci. USA 112, 833-838 (2015).
41. Ahmed, A. A. et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426, 3166-3179 (2014).
42. Frank, M., Walker, R. C., Lanzilotta, W. N., Prestegard, J. H. & Barb, A. W. Immunoglobulin g1 fc domain motions: implications for fc engineering. J. Mol. Biol. 426, 1799-1811 (2014).
43. Teplyakov, A., Zhao, Y. H., Malia, T. J., Obmolova, G. & Gilliland, G. L. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface. Mol. Immunol. 56, 131-139 (2013).
44. Vafa, O. et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65, 114-126 (2014).
45. Koolwijk, P. et al. Interaction between hybrid mouse monoclonal-antibodies and the human high-affinity Igg Fcr, Hufc-Gamma-Ri, on U937-Involvement of only one of the migg heavy-chains in receptor-binding. J. Immunol. 143, 1656-1662 (1989).
46. Mizushima, T. et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 16, 1071-1080 (2011).
47. Kiyoshi, M. et al. Affinity improvement of a therapeutic antibody by structurebased computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-antigen complex. PLoS ONE 9, e87099 (2014).
48. Maenaka, K., van der Merwe, P. A., Stuart, D. I., Jones, E. Y. & Sondermann, P. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 276, 44898-44904 (2001).
49. van den Bedem, H., Bhabha, G., Yang, K., Wright, P. E. & Fraser, J. S. Automated identification of functional dynamic contact networks from X-ray crystallography. Nat. Methods 10, 896-U110 (2013).
50. Pincetic, A. et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707-716 (2014).
51. Asaoka, Y., Hatayama, K., Tsumoto, K., Tomita, M. & Ide, T. Engineering of recombinant human Fcg receptor I by directed evolution. Protein Eng. Des. Sel. 25, 835-842 (2012).
52. Leslie, A. G. The integration of macromolecular diffraction data. Acta Crystallogr. D 62, 48-57 (2006).
53. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72-82 (2006).
54. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658-674 (2007).
55. Idusogie, E. E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178-4184 (2000).
56. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240-255 (1997).
57. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
58. Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr 26, 283-291 (1993).
59. Sakamoto, S. et al. Contributions of interfacial residues of human interleukin15 to the specificity and affinity for its private alpha-receptor. J. Mol. Biol. 389, 880-894 (2009).
60. Cleland, W. W. & Northrop, D. B. Energetics of substrate binding, catalysis, and product release. Methods Enzymol. 308, 3-27 (1999).
61. Hayward, S. & Berendsen, H. J. Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. Proteins 30, 144-154 (1998).